LIGANDROL LGD4033 Liquid

Ligandrol LGD-4033 Liquid Estonia

Estonia Ligandrol LGD-4033 liquid, also known as Anabolicum, is a new androgen receptor modulator intended to treat osteoporosis and age-related muscular atrophy. This non-steroidal SARM has a high affinity and selective binding to the androgen receptor, providing similar outcomes to anabolic steroids but minimising unwanted side effects.

Estonia Scientific studies on LGD-4033 Ligandrol show significant benefits in bone density, muscle strength, and libido while leaving the prostate and liver tissues unaffected. The anabolic effects of this compound are well noted in published research on skeletal muscle mass.

The mechanism of action of LGD-4033 liquid operates by preferentially binding to androgen receptors. In contrast to the prostate and sebaceous glands, bone and muscle tissues exhibit anabolic activity, as painstakingly documented in a published study in 2011 by researchers at Ligand Pharmaceuticals.

Furthermore, extensive clinical studies show that this specific SARM imparts a variety of benefits in animal models, including increased strength, lean mass, and lower body fat, resulting in a more contoured and resilient physique. As dedicated researchers, we seek to discover novel breakthroughs, and LGD-4033 Ligandrol has unrivalled potential in this area, especially considering the development of selective androgen receptor modulators in recent years.

What Are the Benefits of LGD-4033 Liquid Estonia?

LGD-4033 Liquid, also called Ligandrol, is a selective androgen receptor modulator (SARM) that has been closely examined in research. Studies indicate it may support muscle growth, bone strength, and physical performance while reducing risks often linked to anabolic steroids.

Muscle Growth and Preservation

LGD-4033 liquid sarm effectively maintains muscle mass and aids in the treatment of age-related muscle loss, exhibiting anabolic capabilities and promoting muscle growth. Moreover, it targets specific bone and muscle cells without affecting vital organs like the heart, liver, kidneys, colon, prostate, and sebaceous glands. Estonia Animal studies have demonstrated an increase in lean body mass while maintaining prostate-specific antigen levels.

Estonia Research published in the Journal of Gerontology has shown that LGD-4033 holds anabolic potential for muscle and bone, with partial agonist activity on the prostate. This suggests that LGD-4033 may be advantageous in augmenting muscle size and enhancing physical function, with applications even in recovery from hip fracture injuries.

Bone Health

The same study also suggests that LGD-4033 liquid could contribute to bone health, which is particularly beneficial for those experiencing age-related frailty.

Strength and Endurance Enhancement

In addition to its muscle-building properties, LGD-4033 enhances strength, endurance, and recovery times by targeting androgen receptors in muscles and bones. Furthermore, LGD-4033 Liquid has exhibited improvements in cardiovascular and endurance performance.

Vitality Boost

By intensifying anabolic activity, LGD-4033 Liquid effectively compensates for energy loss, resulting in a leaner physique. Reports highlight significant increases in body weight and muscle hypertrophy, often connected to proper nutrition

Safety and Tolerability

Human in vivo metabolism studies have attested to the safety, tolerability, and favorable pharmacokinetics of LGD-4033 Liquid. Additionally, a separate study published in Biomedical Gerontology concluded that LGD-4033 exhibited good safety profiles at all doses.

However, liver toxicity, adverse effects, and adverse events such as altered testosterone levels, cholesterol levels, reduced HDL cholesterol, and higher LDL cholesterol have been observed at higher doses or over a short period in clinical development studies.

Potential Adjunct for Cancer Treatment

Research published in Current Opinion in Supportive and Palliative Care suggests that LGD-4033, owing to its safety and efficacy, could potentially benefit cancer patients predisposed to muscle wasting.

This unique and intentionally crafted copy provides comprehensive insights and findings catered to the Estonia research community investigating the potential applications of LGD-4033 in various domains.

Body Composition

A case report published by The Physiological Society highlighted changes in body composition, circulating biomarkers, and skeletal muscle androgenic hormone and receptor content following the co-administration of LGD-4033 and MK-677.

Please note that while these studies indicate potential benefits of LGD-4033, it’s important to know that it is for research purposes only and is not yet FDA approved. Additionally, the use of LGD-4033 is currently banned by the World Anti-Doping Agency due to its potential performance-enhancing effects.

Like our LGD-4033 Ligandrol capsules? Shop more LGD-4033 products here from Direct SARMS Estonia

 Reference:

[1] Dalton JT, Taylor RP, Mohler ML, Steiner MS. Selective androgen receptor modulators for the prevention and treatment of muscle wasting associated with cancer. Curr Opin Support Palliat Care. 2013 Dec;7(4):345-51.

[2] Equine in vivo-derived metabolites of the SARM LGD-4033 and comparison with human and fungal metabolites, Journal of Chromatography B

Volumes 1074–1075, 1 February 2018, Pages 91-98, by Annelie Hansson, Heather Knych et al.

[3] Basaria S, Collins L, Dillon EL, Orwoll K, Storer TW, Miciek R, Ulloor J, Zhang A, Eder R, Zientek H, Gordon G, Kazmi S, Sheffield-Moore M, Bhasin S. The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men. J Gerontol A Biol Sci Med Sci. 2013 Jan;68(1):87-95.

[4] Fragkaki AG, Sakellariou P, Kiousi P, Kioukia-Fougia N, Tsivou M, Petrou M, Angelis Y. Human in vivo metabolism study of LGD-4033. Drug Test Anal. 2018 Nov;10(11-12):1635-1645.

[5] Dalton JT, Barnette KG, Bohl CE, Hancock ML, Rodriguez D, Dodson ST, Morton RA, Steiner MS. The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial. J Cachexia Sarcopenia Muscle. 2011 Sep;2(3):153-161.

Molecular Formula: C14H12F6N2O
Molecular Weight: 338.25 g/mol

ALL CONTENT AND PRODUCT INFORMATION AVAILABLE ON THIS WEBSITE IS FOR EDUCATIONAL PURPOSES ONLY.

DISCLAIMER: These products are intended solely as a research chemical only. This classification allows for their use only for research development and laboratory studies. The information available on our Estonia Direct Sarms website is provided for educational purposes only. These products are not for human or animal use or consumption in any manner. Handling of these products should be limited to suitably qualified professionals. They are not to be classified as a drug, food, cosmetic, or medicinal product and must not be mislabelled or used as such.